LONGEVA.

MIF-1: adverse events and evidence limits

The abstract studying MIF-1 (Pro-Leu-Gly-NH₂) in 20 patients with major depression describes subcutaneous administration but gives no adverse-event frequencies. [1]

In another crossover study, eight men received an MIF-1 capsule before morphine: experimental analgesia decreased. This is an interaction signal, not a complication frequency or proof of catalog-product equivalence. [2]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events20 patients with major depression, subcutaneous MIF-1The abstract describes subcutaneous administration but gives no adverse-event frequencies[1]
Reduced morphine analgesia (interaction signal)Eight men, crossover study: an MIF-1 capsule before morphineExperimental analgesia decreased; an interaction signal, not a complication frequency[2]

References

  1. R H Ehrensing et al. (1994). Improvement in major depression after low subcutaneous doses of MIF-1 https://doi.org/10.1016/0165-0327(94)90098-1.
  2. R H Ehrensing et al. (1984). Antagonism of morphine analgesia by prolyl-leucyl-glycinamide (MIF-1) in humans. https://doi.org/10.1016/S0091-3057(84)80083-0.